Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 23, 2015 11:49 PM ET

Pharmaceuticals

Company Overview of ImmusanT, Inc.

Company Overview

ImmusanT, Inc., a biotechnology company, develops treatment and diagnostic and monitoring tools to manage patients with celiac disease. The company offers Nexvax2, a peptide-based therapeutic vaccine that is designed to re-establish patients’ tolerance to the toxic effects of gluten, a protein in wheat, barley, and rye and allow them to return to a normal diet. ImmusanT, Inc. was founded in 2010 and is based in Cambridge, Massachusetts with clinical trials in New Zealand, Australia, and the United States.

One Kendall Square

Suite B2004

Cambridge, MA 02139

United States

Founded in 2010

Phone:

617-299-8399

Fax:

617-300-8892

Key Executives for ImmusanT, Inc.

Founder, Chief Executive Officer, President and Director
Chief Financial Officer and Secretary pro tem
Director of Finance and Operations
Consulting Scientist
Senior Scientific/Technical Advisor and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2014.

ImmusanT, Inc. Key Developments

ImmusanT, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014

ImmusanT, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 . Venue: The Palace Hotel, San Francisco, CA 94105, United States.

ImmusanT Names Ferdinand E. Massari as Chief Medical Officer

ImmusanT announced that Ferdinand E. Massari, MD has joined the biopharmaceutical company as Senior Vice President, Development and Chief Medical Officer. Dr. Massari will oversee the clinical development program for the therapeutic vaccine Nexvax2(R) for celiac disease and its companion diagnostic, as well as future development programs for other autoimmune diseases. Massari has over 20 years of experience in all stages of drug development and comes to ImmusanT having most recently served as a consultant providing product candidate evaluation and clinical plan development services to companies and investors. Previously, Dr. Massari was Global Head and Vice President of Clinical and Medical Affairs at Shire Human Genetic Therapies, where he was responsible for the oversight of global development of products to treat rare genetic disorders. Earlier, Dr. Massari served as Senior Vice President of Drug Development and Chief Medical Officer at Coley Pharmaceutical Group where he oversaw the development of novel therapeutics for hepatitis C infection and lupus. Dr. Massari has held executive positions at Pfizer where he led clinical programs for ZYVOX (linezolid), one of the most successful hospital antibiotics to date.

Similar Private Companies By Industry

Company Name Region
Johnson Matthey Pharmaceutical Materials, Inc. United States
Selexys Pharmaceuticals Corporation United States
QPS, L.L.C. United States
Revalesio Corporation United States
PolyMedica Pharmaceuticals (U.S.A.), Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 19, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ImmusanT, Inc., please visit www.immusant.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.